Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;12(10):951-960.
doi: 10.1080/17474124.2018.1522248. Epub 2018 Sep 20.

Elobixibat for the treatment of constipation

Victor Chedid  1 , Priya Vijayvargiya  1 , Michael Camilleri  1   2
Affiliations

Elobixibat for the treatment of constipation

Victor Chedid et al. Expert Rev Gastroenterol Hepatol. 2018 Oct.

Abstract

Chronic idiopathic constipation (CC) is highly prevalent worldwide. A subset of patients with CC have reduced fecal (and by inference, intra-colonic) bile acids (BA). Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC. BAs accelerate colonic transit and increase colonic secretion. Therefore, IBAT inhibitors have potential to treat patients with CC. Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor. In humans, elobixibat accelerated colonic transit. In phase 2A, 2B and 3 studies in CC, elobixibat was efficacious, well tolerated and safe. An open-label, phase 3 trial (52 weeks) confirmed the safety of elobixibat. Elobixibat reduces LDL cholesterol, increases serum GLP-1, and has potential in metabolic syndrome. Expert commentary: Uniquely among current treatments of CC, elobixibat stimulates both motor and secretory functions in the colon. These dual effects suggest that, when approved, elobixibat may be a first-line choice for constipation associated with colonic BA deficiency and a second-line treatment for all patients with CC and constipation-predominant irritable bowel syndrome. Further studies are required to confirm efficacy for relief of CC. Once approved, elobixibat will likely become a second-line choice for treatment of CC.

Keywords: Bile acid; enterohepatic circulation; ileal bile acid transporter (IBAT); irritable bowel syndrome; pharmacodynamics; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Chemical structures and colonic functions of individual bile acids. Modified with permission from reference 35.
BA, bile acids; CDCA, chenodeoxycholic acid; CA, cholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; UDCA, ursodeoxycholic acid
Figure 2.
Figure 2.
Enterohepatic circulation. The left panel shows the enterohepatic circulation in patients without bile acid malabsorption. The right panel demonstrates enterohepatic circulation in patients with bile acid malabsorption. Reproduced from reference [39] (no permission needed; it is a free PMC article). IBAT, ileal bile acid transporter; IBS, irritable bowel syndrome;
Figure 3.
Figure 3.
Two dimensional molecular structure of elobixibat
See this image and copyright information in PMC

References

    1. Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A, Saenger A, Girtman A, Zinsmeister AR: Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2013) 11(10):1270–1275 e1271. - PMC - PubMed
    1. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, Dyer RB, Lamsam J, Zinsmeister AR: Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 10(9):1009–1015 e1003. - PMC - PubMed
    1. Wedlake L, A’Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ: Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by sehcat scanning in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology & therapeutics (2009) 30(7):707–717. - PubMed
    1. Valentin N, Camilleri M, Altayar O, Vijayvargiya P, Acosta A, Nelson AD, Murad MH. Biomarkers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis. Gut (2016) 65(12):1951–1959. - PubMed
    1. Vijayvargiya P, Camilleri M: Update on bile acid malabsorption: Finally ready for prime time? Current Gastroenterology Reports (2018) 20(3):10. - PubMed

MeSH terms

LinkOut - more resources